Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to provide expanded access (compassionate use) of 3,4
diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).